Table 1.
Clinical features of patients with mild COVID-19.
| Characteristic | All patients (n = 332) | Stable group (n = 274, 82.5%) | Intensive care group (n = 58, 17.5%) | P value |
|---|---|---|---|---|
| Sex | ||||
| Male, n (%) | 132 (39.8) | 105 (38.3) | 27 (46.6) | 0.245 |
| Female, n (%) | 200 (61.2) | 169 (61.7) | 31 (53.4) | 0.245 |
| Age, median (IQR) | 51 (40-59) | 50.5 (40-59) | 52 (42-60) | 0.478 |
|
| ||||
| Symptoms | ||||
| Fever, n (%) | 177 (63.2) | 142 (63.4) | 35 (62.5) | 0.901 |
| Cough, n (%) | 108 (38.4) | 88 (39.1) | 20 (35.7) | 0.640 |
| Fatigue, n (%) | 39 (13.9) | 28 (12.5) | 11 (19.6) | 0.167 |
| Chest tightness, n (%) | 32 (11.5) | 15 (6.7) | 17 (29.3) | <0.001 |
| Diarrhea, n (%) | 11 (3.9) | 8 (3.6) | 3 (5.4) | 0.538 |
| Headache, n (%) | 7 (2.5) | 6 (2.7) | 1 (1.8) | 0.702 |
| Sore throat, n (%) | 4 (1.4) | 2 (0.9) | 2 (3.4) | 0.181 |
| Rhinorrhea, n (%) | 4 (1.4) | 4 (1.8) | 0 (0.0) | 0.587 |
| Myalgia, n (%) | 12 (4.3) | 9 (4.0) | 3 (5.4) | 0.658 |
| Toothache, n (%) | 2 (0.6) | 0 (0.0) | 2 (3.4) | 0.030 |
|
| ||||
| Comorbidities | ||||
| CV conditions, n (%) | 48 (14.5) | 25 (7.5) | 23 (39.7) | <0.001 |
| CHD, n (%) | 11 (3.3) | 1 (0.4) | 10 (17.2) | <0.001 |
| Hypertension, n (%) | 38 (11.4) | 21 (7.7) | 17 (27.9) | <0.001 |
| Diabetes, n (%) | 11 (3.3) | 7 (2.6) | 4 (6.9) | 0.106 |
| Lung disease, n (%) | 7 (2.1) | 4 (1.5) | 3 (5.2) | 0.105 |
| Radiologic abnormality,n(%) | 201 (65.5) | 183 (70.1) | 18 (36.7) | <0.001 |
|
| ||||
| Positive SARS-CoV-2 testing by RT-PCR | ||||
| Twice or more, n (%) | 72 (23.0) | 48 (18.3) | 24 (48.0) | <0.001 |
| Once, n (%) | 241 (77.0) | 215 (81.7) | 26 (74) | <0.001 |
|
| ||||
| Laboratory findings | ||||
| Red blood cell count (∗1012/L), median (IQR) | 4.39 (4.05-4.73) | 4.39 (4.05-4.73) | 4.42 (4.02-4.76) | 0.863 |
| White cell count (∗109/L), median (IQR) | 5.25 (4.49-6.37) | 5.19 (4.47-6.33) | 5.62 (4.88-6.58) | 0.058 |
| Neutrophil count (∗109/L), median (IQR) | 3.21 (2.57-4.08) | 3.18 (2.55-3.98) | 3.49 (2.67-4.27) | 0.143 |
| Lymphocyte count (∗109/L), median (IQR) | 1.61 (1.26-1.91) | 1.58 (1.26-1.86) | 1.80 (1.26-2.17) | 0.057 |
| NLR, median (IQR) | 2.1 (1.6-2.7) | 2.1 (1.6-2.7) | 2.1 (1.5-2.8) | 0.911 |
| Platelet count (∗109/L), median (IQR) | 258 (216-310) | 267 (218-324) | 223 (194-269) | 0.003 |
| Hemoglobin (g/L), median (IQR) | 135 (125-145) | 135 (126-144) | 135 (122-145) | 0.781 |
|
| ||||
| C-reactive protein | ||||
| <10.00 mg/L | 261 (85.0) | 217 (84.4) | 44 (88.0) | 0.518 |
| ≥10.00 mg/L | 46 (15.0) | 40 (15.6) | 6 (12.0) | 0.518 |
| Median length of symptoms onset to admission (days) (IQR) | 12 (8-16) | 12 (8-15) | 13 (6-21) | 0.679 |
| Median length of temporary hospital stay (days) (IQR) | 14 (10-19) | 14 (10-19) | 15 (11-21.5) | 0.322 |
IQR: interquartile range; NLR: neutrophil to lymphocyte ratio; CV: cardiovascular; CHD: coronary heart disease.